InvestorWire NewsRoom


Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Growth Strategy Moves Forward with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) Partnership for Ketamine-Assisted Psychotherapy Distribution
November 4, 2021

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Growth Strategy Moves Forward with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) Partnership for Ketamine-Assisted Psychotherapy Distribution

  • The distribution component unlocks a new revenue source for the company, helping drive future growth
  • MINDCURE’s platform was built as a digital tool and distribution platform, and has already been used for deployment and distribution of ketamine for depression and pain
  • Digital therapeutics market is projected to reach USD $13.1 billion by 2026 from USD $3.4 billion in 2021 at a CAGR of 31.4 %, a substantial increase primarily driven by the COVID-19 pandemic and the stressors associated with it
  • MINDCURE’s target areas and value proposition list numerous benefits for therapists, patients, payers, and drug and protocol developers, through the proprietary technology and platform.

A recent non-binding Letter of Intent (“LOI”) was signed between Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, and Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF), a biotech company with clinical operations researching, developing, and delivering psychedelic medicine to treat addiction. Under the LOI, MINDCURE becomes a distributor of Awakn’s ketamine-assisted psychotherapy for Alcohol Use Disorder in the United States and Canada, through its proprietary digital therapeutics platform, iSTRYM.

This is MINDCURE’s first international partnership with industry leaders developing rigorous psychedelics protocols and drugs that can be distributed through the company’s platform to support both therapists and patients. As well as distributing its partners’ protocols, the company will also be distributing its own protocols through iSTRYM. 

With the minimum viable product (“MVP”) version of iSTRYM already released into partner clinics across North America, the company expects to partner with 75 clinics in both Canada and the U.S. when beginning full commercia deployment in early 2022, and to double that number by Q4 2022. The distribution component of iSTRYM opens up a new source of revenue for the company, which will help fuel further growth and expansion strategies.

MINDCURE’s digital therapeutics (“DTx”) platform was built to be scaled at a global level as a drug-agnostic digital tool and distribution platform. The company’s own protocols of ketamine for depression and ketamine for pain have already been created, with ketamine for an undisclosed indication currently in development. 

With additional revenue to drive growth goals, the company expects to be able to leverage multiple emerging opportunities on the fast-growing digital therapeutics market. Globally, the digital therapeutics market is projected to reach USD $13.1 billion by 2026 from USD $3.4 billion in 2021, at a CAGR of 31.4% ( 

DTx is a subdivision of digital health, but not all digital health solutions are DTx. According to the Digital Therapeutics Alliance, DTx deliver evidence-based therapeutic interventions that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies, to optimize patient care and health outcomes. The rise in DTx can be attributed to the mass use of smart devices by consumers. Another element that has driven the demand for digital therapies has been the COVID-19 pandemic, with its associated stressors and increase in mental health conditions. 

A variety of segments stand to benefit from DTx and MINDCURE’s proprietary platform – therapists, patients, payers, and drug and protocol developers. Each segment has its own value proposition, according to the company:

  • Therapist Value Proposition:
  • Cost reduction
  • More favorable outcomes
  • An increased portfolio of protocols that can expand guidance on practice and payer code guidance
  • Patient Value Proposition
    • Improved compliance
    • Outcomes are optimized
    • Proofing of the safety and efficacy
  • Payer Value Proposition
    • Access to cumulative data on the patient outcomes and compliance
  • Drug and Protocol Developer Value Proposition
    • A partner for distribution and sales
    • Provide line-of-sight to compliance; de-risk new protocol deployment

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).